Appointment to the Board
Bruno Angelici was appointed to the Vectura Board on 1 December 2013 and became Non-Executive Chairman in February 2014. Following the merger with Skyepharma in June 2016, Bruno became Chairman of the enlarged Vectura Group plc.
Experience and expertise
Bruno has an MBA (Kellogg School of Management) and business and law degrees from Reims.
Bruno’s career includes senior management roles in pharmaceutical and medical device companies. Bruno retired from AstraZeneca in 2010 as executive vice president international after a 20-year career. He was responsible for Europe, Japan, Asia-Pacific, Latin America, the Middle East and Africa, having originally joined as president of ICI Pharmaceuticals France. He was a non-executive director of Novo Nordisk A/S, a global healthcare company and world leader in diabetes care. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international business leadership experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries.
Current external appointments
Bruno is a non-executive director of Smiths Group plc, a technology group. He was a member of the global advisory board of Takeda Pharmaceutical Company Ltd, Japan, the largest pharmaceutical company in Asia until the end of 2017, and a member of the supervisory board of Wolters Kluwer NV, a global information services and publishing company.